Cargando…
Association between cancer‐specific adverse event triggers and mortality: A validation study
BACKGROUND: As there are few validated measures of patient safety in clinical oncology, creating an efficient measurement instrument would create significant value. Accordingly, we sought to assess the validity of a novel patient safety measure by examining the association of oncology‐specific trigg...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300390/ https://www.ncbi.nlm.nih.gov/pubmed/32285614 http://dx.doi.org/10.1002/cam4.3033 |
_version_ | 1783547578471677952 |
---|---|
author | Weingart, Saul N. Nelson, Jason Koethe, Benjamin Yaghi, Omar Dunning, Stephan Feldman, Albert Kent, David Lipitz‐Snyderman, Allison |
author_facet | Weingart, Saul N. Nelson, Jason Koethe, Benjamin Yaghi, Omar Dunning, Stephan Feldman, Albert Kent, David Lipitz‐Snyderman, Allison |
author_sort | Weingart, Saul N. |
collection | PubMed |
description | BACKGROUND: As there are few validated measures of patient safety in clinical oncology, creating an efficient measurement instrument would create significant value. Accordingly, we sought to assess the validity of a novel patient safety measure by examining the association of oncology‐specific triggers and mortality using administrative claims data. METHODS: We examined a retrospective cohort of 322 887 adult cancer patients enrolled in commercial or Medicare Advantage products for one year after an initial diagnosis of breast, colorectal, lung, or prostate cancer in 2008‐2014. We used diagnosis and procedure codes to calculate the prevalence of 16 cancer‐specific "triggers"–events that signify a potential adverse event. We compared one‐year mortality rates among patients with and without triggers by cancer type and metastatic status using logistic regression models. RESULTS: Trigger events affected 19% of patients and were most common among patients with metastatic colorectal (41%) and lung (50%) cancers. There was increased one‐year mortality among patients with triggers compared to patients without triggers across all cancer types in unadjusted and multivariate analyses. The increased mortality rate among patients with trigger events was particularly striking for nonmetastatic prostate cancer (1.3% vs 7.5%, adjusted odds ratio 1.96 [95% CI 1.49‐2.57]) and nonmetastatic colorectal cancer (4.1% vs 11.7%, 1.44 [1.19‐1.75]). CONCLUSIONS: The association between adverse event triggers and poor survival among a cohort of cancer patients supports the validity of a cancer‐specific, administrative claims‐based trigger tool. |
format | Online Article Text |
id | pubmed-7300390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73003902020-06-18 Association between cancer‐specific adverse event triggers and mortality: A validation study Weingart, Saul N. Nelson, Jason Koethe, Benjamin Yaghi, Omar Dunning, Stephan Feldman, Albert Kent, David Lipitz‐Snyderman, Allison Cancer Med Cancer Prevention BACKGROUND: As there are few validated measures of patient safety in clinical oncology, creating an efficient measurement instrument would create significant value. Accordingly, we sought to assess the validity of a novel patient safety measure by examining the association of oncology‐specific triggers and mortality using administrative claims data. METHODS: We examined a retrospective cohort of 322 887 adult cancer patients enrolled in commercial or Medicare Advantage products for one year after an initial diagnosis of breast, colorectal, lung, or prostate cancer in 2008‐2014. We used diagnosis and procedure codes to calculate the prevalence of 16 cancer‐specific "triggers"–events that signify a potential adverse event. We compared one‐year mortality rates among patients with and without triggers by cancer type and metastatic status using logistic regression models. RESULTS: Trigger events affected 19% of patients and were most common among patients with metastatic colorectal (41%) and lung (50%) cancers. There was increased one‐year mortality among patients with triggers compared to patients without triggers across all cancer types in unadjusted and multivariate analyses. The increased mortality rate among patients with trigger events was particularly striking for nonmetastatic prostate cancer (1.3% vs 7.5%, adjusted odds ratio 1.96 [95% CI 1.49‐2.57]) and nonmetastatic colorectal cancer (4.1% vs 11.7%, 1.44 [1.19‐1.75]). CONCLUSIONS: The association between adverse event triggers and poor survival among a cohort of cancer patients supports the validity of a cancer‐specific, administrative claims‐based trigger tool. John Wiley and Sons Inc. 2020-04-13 /pmc/articles/PMC7300390/ /pubmed/32285614 http://dx.doi.org/10.1002/cam4.3033 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Weingart, Saul N. Nelson, Jason Koethe, Benjamin Yaghi, Omar Dunning, Stephan Feldman, Albert Kent, David Lipitz‐Snyderman, Allison Association between cancer‐specific adverse event triggers and mortality: A validation study |
title | Association between cancer‐specific adverse event triggers and mortality: A validation study |
title_full | Association between cancer‐specific adverse event triggers and mortality: A validation study |
title_fullStr | Association between cancer‐specific adverse event triggers and mortality: A validation study |
title_full_unstemmed | Association between cancer‐specific adverse event triggers and mortality: A validation study |
title_short | Association between cancer‐specific adverse event triggers and mortality: A validation study |
title_sort | association between cancer‐specific adverse event triggers and mortality: a validation study |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300390/ https://www.ncbi.nlm.nih.gov/pubmed/32285614 http://dx.doi.org/10.1002/cam4.3033 |
work_keys_str_mv | AT weingartsauln associationbetweencancerspecificadverseeventtriggersandmortalityavalidationstudy AT nelsonjason associationbetweencancerspecificadverseeventtriggersandmortalityavalidationstudy AT koethebenjamin associationbetweencancerspecificadverseeventtriggersandmortalityavalidationstudy AT yaghiomar associationbetweencancerspecificadverseeventtriggersandmortalityavalidationstudy AT dunningstephan associationbetweencancerspecificadverseeventtriggersandmortalityavalidationstudy AT feldmanalbert associationbetweencancerspecificadverseeventtriggersandmortalityavalidationstudy AT kentdavid associationbetweencancerspecificadverseeventtriggersandmortalityavalidationstudy AT lipitzsnydermanallison associationbetweencancerspecificadverseeventtriggersandmortalityavalidationstudy |